Vidriales M B, Orfao A, López-Berges M C, González M, López-Macedo A, Ciudad J, López A, Cañizo M C, Garcia M A, San Miguel J F
Servicio de Hematología, Hospital Clínico Universitario, Salamanca, Spain.
Cytometry. 1995 Mar 15;22(1):22-5. doi: 10.1002/cyto.990220105.
In the present study the DNA cell content of 205 de novo acute myeloblastic leukemia (AML) patients is analyzed at flow cytometry in order to determine both the incidence of DNA aneuploidy in AML patients and the clinical and biological characteristics of AML aneuploid cases. All technical procedures were performed in accordance with the proposed guidelines of the DNA Cytometric Consensus Conference. Our results show that the incidence of DNA aneuploidy is quite low (4.8%), with most cases (n = 8) hyperdiploid and only a small proportion (n = 2) hypodiploid. No major differences were detected between the aneuploid and diploid cases with respect to the clinical and prognostic disease characteristics. Regarding the immunophenotype of the blast cells, the aneuploid cases displayed both a higher incidence of immature myeloblastic phenotype and a greater expression of lymphoid-associated antigens. In summary, our results show that AML patients display a quite low incidence of DNA aneuploidy and that despite the fact that these cases do not display particular clinical characteristics, they show an association with the expression of lymphoid-related markers.
在本研究中，对205例初发急性髓系白血病（AML）患者的DNA细胞含量进行了流式细胞术分析，以确定AML患者中DNA非整倍体的发生率以及AML非整倍体病例的临床和生物学特征。所有技术程序均按照DNA细胞计量共识会议提出的指南进行。我们的结果表明，DNA非整倍体的发生率相当低（4.8%），大多数病例（n = 8）为超二倍体，只有一小部分（n = 2）为亚二倍体。在临床和预后疾病特征方面，非整倍体病例和二倍体病例之间未检测到重大差异。关于原始细胞的免疫表型，非整倍体病例显示出不成熟髓系原始细胞表型的发生率更高，以及淋巴样相关抗原的表达更强。总之，我们的结果表明，AML患者中DNA非整倍体的发生率相当低，并且尽管这些病例没有表现出特定的临床特征，但它们与淋巴样相关标志物的表达有关。
